Who Paid My Doc
Sorangel Ortiz Rodriguez
Registered Nurse, General Practice Ormond Beach, FL Nurse Practitioner
NPI 1912604695 CMS profile 11508815
325 Clyde Morris Blvd Ste 340, Ormond Beach, FL 32174
General payments
$516
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Sorangel Ortiz Rodriguez of Ormond Beach, FL is reported in the CMS Open Payments database as having received $516 across 26 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 74th percentile of Registered Nurse, General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $57 | 3 | |
| 2024 | General | $252 | 13 | |
| 2023 | General | $206 | 10 |
Beside peers
- Sorangel Ortiz Rodriguez
- Registered Nurse, General Practice median
- Middle half of Registered Nurse, General Practice
- National median
In program year 2025, general payments to Sorangel Ortiz Rodriguez were reported at $57. Among 146 Registered Nurse, General Practice profiles paid that year, the median was $117 and the middle half received between $27 and $348.
Show as a table
| Year | Sorangel Ortiz Rodriguez | Registered Nurse, General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $92 | $30–$313 | $132 |
| 2022 | $0 | $85 | $28–$243 | $149 |
| 2023 | $206 | $121 | $51–$290 | $160 |
| 2024 | $252 | $127 | $42–$316 | $164 |
| 2025 | $57 | $117 | $27–$348 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 106 drugsPart D claims
5,427
Drug cost
$411,852
Branded share of claims
14.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 63 | $86,083 | |
| Eliquis Apixaban | Brand | 48 | $64,546 | |
| Mounjaro Tirzepatide | Brand | 33 | $39,761 | |
| Xarelto Rivaroxaban | Brand | 21 | $30,141 | |
| Ozempic Semaglutide | Brand | 19 | $28,728 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 16 | $28,328 | |
| Farxiga Dapagliflozin Propanediol | Brand | 18 | $26,719 | |
| Entresto Sacubitril/Valsartan | Brand | 16 | $23,252 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 16 | $8,766 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 141 | $6,320 |
The 10 drugs with the highest cost, of 106 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 7 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| FARXIGA |
|
$72 | 18 | — |
| TRELEGY ELLIPTA |
|
$63 | 63 | — |
| AIRSUPRA |
|
$18 | — | — |
| MOUNJARO |
|
$10 | 33 | — |
| ZEPBOUND |
|
$10 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 7 in the dashboard with a free accountRecords
26 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Registered Nurse, General Practice in Florida
Robert Hall
Registered Nurse, General Practice · Jupiter, FL
Bridget Martin
Registered Nurse, General Practice · Miami Beach, FL
Gabriela Quintana
Registered Nurse, General Practice · Doral, FL
Leaanne Griffis
Registered Nurse, General Practice · Jacksonville, FL
Nancy Pena
Registered Nurse, General Practice · Miami, FL
Carline Severe
Registered Nurse, General Practice · Boynton Beach, FL
Related records
Registered Nurse, General Practice in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Registered Nurse, General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.